LRMR Larimar Therapeutics, Inc. Insider Trading

Director SHERMAN JEFFREY W purchased 5,000 shares of LRMR at $5.00 on 2026-02-27; cluster pattern with 3 other insiders buying in past 14 days.

Director Sherman Jeffrey W acquired 5,000 shares at $5.00, establishing an initial position in Larimar Therapeutics at a price now 4.4% above the transaction level ($5.23 current). The transaction is part of a cluster pattern with 3 other insiders also purchasing within the past 14 days, indicating coordinated board-level activity. The company is unprofitable with a net loss of $-47.7M in the latest full year and zero revenue in the latest quarter, characteristic of a clinical-stage or early-stage biotech. The stock has appreciated 67.6% over the past 90 days and 47.7% over the past 30 days, placing it near its 52-week high of $5.95, yet the cluster buying continues despite this elevated valuation context.

Director Flynn James E purchases 5,000,000 shares at $5.00 for $25,000,000, raising holdings to 6.21M shares (+413.9%)

Flynn James E, a Director, executed 4 separate purchases totaling 5,000,000 (5.00M shares) for $25,000,000.00 on 2026-02-27 at a blended average price of $5.00, substantially increasing his position from 1.21M to 6.21M shares. This represents a major commitment of capital ($25.0M) and a dramatic 413.9% increase relative to pre-transaction holdings. His prior buys at Larimar have demonstrated strong performance: all 3 prior trades at LRMR (each executed on 2025-07-31) posted +34.7% returns over 90 days, and his cross-ticker track record shows 5 prior buys averaging +19.5% 90-day returns with a 60% win rate. The current stock price of $5.23 is 52-week low near the $1.71–$5.95 range and up +47.7% over 30 days and +67.6% over 90 days. Notably, a cluster pattern is evident: 3 other insiders also bought within the past 14 days, signaling coordinated accumulation at the board level.

Director Thomas Frank E buys 5,000 shares of LRMR at $5.00; stock up 47.7% in 30 days, but company unprofitable with -$47.7M net income.

Thomas Frank E increased his stake in Larimar Therapeutics by 250.0% to 7,000 shares via a $25,000 open-market purchase at $5.00 on 2026-02-27. The stock is currently trading at $5.23, up 47.7% over the past 30 days and 67.6% over 90 days, but this recent price strength does not align with the company's fundamentals: Larimar reported zero revenue in its latest quarter and a net loss of -$47.7M for the most recent full fiscal year. The insider's prior buy at this same ticker on 2024-02-14 was poorly timed, with the stock declining 28.4% over the subsequent 90 days, signaling a pattern of unfavorable purchase timing. Additionally, a cluster of 3 other insiders also purchased shares within the past 14 days, which warrants scrutiny given the widening gap between current valuations and the underlying unprofitable, revenue-less business.

Director Hamilton Thomas Edward bought 100,000 LRMR shares at $5.00 for $500,000; cluster of 3 concurrent insiders also buying amid unprofitable operations.

Hamilton Thomas Edward (Director) purchased 100,000 shares at $5.00 on 2026-02-27, increasing his holdings by 17.7% to 664,798 shares total. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days. Against this backdrop, the company reported zero revenue in its latest quarter and negative net income of -$47,712,000.00, with an overall unprofitable fiscal year. The stock has appreciated 47.7% over 30 days and 67.6% over 90 days from unnamed reference points, though it remains 12.1% below its 52-week high of $5.95. Notably, this director's prior buy at LRMR on 2024-02-16 generated negative 90-day returns of -15.0%, and his cross-ticker track record shows a 0.00% win rate on buys with an average 90-day return of -15.0%, suggesting a pattern of poor timing on purchase decisions. The concurrent buying activity by multiple insiders, while potentially signaling internal optimism, occurs in a fundamentally challenged environment and must be weighed against the insider's historical execution record.

Director James E Flynn purchases 9.38M shares for $30.0M at $3.20 at unprofitable Larimar Therapeutics (LRMR)

Flynn James E, a Director, executed 3 separate purchases totaling 9,375,000 shares for $30,000,000.00 at $3.20 on 2025-07-31, bringing his post-transaction holdings to 7,321,129 shares. The scale of this acquisition—$30.0M deployed at a single price point on a single day—represents a material capital commitment to the company. LRMR is unprofitable, reporting net income of $-29,281,000.00 and zero revenue in the latest quarter, with a market cap of $211,932,322.52; Flynn's purchase now represents a substantial position in an early-stage or distressed biotech. Against his own same-ticker history, Flynn's prior buy at LRMR on 2024-02-16 showed 90-day performance of -15.0%, and his cross-ticker buy track record shows a 0.00% win rate at the 90-day mark, yet the stock has risen 57.6% over the past 90 days from its lows (currently $3.31, up 3.4% in 30 days). The timing and magnitude of this purchase, combined with the company's negative financials, warrant examination of whether this reflects insider valuation assessment, participation commitment, or other material information asymmetries.